

Guangying Du

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1952730/publications.pdf>

Version: 2024-02-01

15
papers

156
citations

1307594

7
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

341
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT _{2A} receptor antagonists/inverse agonists. <i>European Journal of Medicinal Chemistry</i> , 2022, 234, 114246.	5.5	5
2	9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors. <i>Future Medicinal Chemistry</i> , 2022, 14, 991-1003.	2.3	0
3	Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113718.	5.5	3
4	(+)-9-Trifluoroethoxy- β -Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia. <i>Frontiers in Pharmacology</i> , 2021, 12, 770377.	3.5	1
5	Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842095058.	2.1	5
6	PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice. <i>PLoS ONE</i> , 2020, 15, e0228339.	2.5	22
7	PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer. <i>Toxicology and Applied Pharmacology</i> , 2020, 398, 115019.	2.8	12
8	PCC0208018 exerts antitumor effects by activating effector T cells. <i>International Journal of Immunopathology and Pharmacology</i> , 2019, 33, 205873841984336.	2.1	4
9	Pharmacokinetics of S-EPA, and its inhibition on indoleamine 2,3-dioxygenase: a case of sulfur-substitution affecting distributions in blood cells. <i>Xenobiotica</i> , 2019, 49, 1338-1343.	1.1	2
10	PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models. <i>International Journal of Immunopathology and Pharmacology</i> , 2018, 32, 205873841878799.	2.1	23
11	Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor. <i>Bioanalysis</i> , 2018, 10, 1335-1344.	1.5	12
12	Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. <i>International Journal of Immunopathology and Pharmacology</i> , 2017, 30, 215-226.	2.1	33
13	Preparation, Pharmacokinetics, Biodistribution, Antitumor Efficacy and Safety of Lx2-32c-Containing Liposome. <i>PLoS ONE</i> , 2014, 9, e114688.	2.5	6
14	NSK-01105, a Novel Sorafenib Derivative, Inhibits Human Prostate Tumor Growth via Suppression of VEGFR2/EGFR-Mediated Angiogenesis. <i>PLoS ONE</i> , 2014, 9, e115041.	2.5	13
15	Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN- γ production. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1727-1736.	2.5	15